Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

NCT04375384 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Metastatic Head-and-neck Squamous-cell Carcinoma

Interventions

DRUG: Cetuximab
OTHER: Questionnaire administration
OTHER: Quality of life assessment

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]